How is TXA2 Synthesized?
Thromboxane A2 is synthesized in the body during the metabolism of arachidonic acid. This pathway is driven by the enzyme cyclooxygenase-1 (COX-1). This enzyme isoform is constitutive, meaning it is expressed continuously in the body and participates in basal homeostasis.
During the cyclooxygenase pathway, cyclic endoperoxides are formed from arachidonic acid, which are then converted into TXA2. Additionally, during chronic inflammation, thromboxanes (including TXA2) are synthesized by macrophages anchored at the site of tissue injury via fibronectin molecules.
Mechanism of Action in Thrombus Formation
TXA2 is essential for the formation of the primary hemostatic plug (platelet plug). The process occurs in several sequential steps:
- Activation and degranulation — following initial adhesion to the damaged vascular surface, platelets become activated. Activated platelets release granule contents, including ADP, and simultaneously synthesize and secrete TXA2.
- Positive feedback — released TXA2 binds to receptors on the surface of the secreting platelet and neighboring platelets, amplifying their activation and recruiting more cells to the site.
- Intracellular signaling — receptor stimulation leads to an increase in cytosolic calcium ion ($Ca^{2+}$) concentration within the platelets.
- Fibrinogen binding — elevated intracellular calcium triggers a conformational change in GP IIb/IIIa receptors on the cell membrane. Activated GP IIb/IIIa receptors bind fibrinogen molecules, which act as bridges between cells, cross-linking them into a platelet aggregate.
Effect on Vascular Tone and Clinical Significance
The pathogenesis of many cardiovascular diseases involves an imbalance of vasoactive substances. TXA2 is a metabolite with potent hypertensive (pressor) activity.
TXA2 induces vasoconstriction and serves as one of the key mediators responsible for functional narrowing (vasospasm) of coronary arteries.
Pharmacological Regulation
The synthesis of thromboxane A2 can be suppressed using pharmacologic agents that target hemostasis. The primary target in this pathway is the cyclooxygenase enzyme.
- Aspirin (acetylsalicylic acid) — irreversibly acetylates and blocks COX, interrupting the conversion of arachidonic acid into cyclic endoperoxides and subsequently TXA2.
- NSAIDs (nonsteroidal anti-inflammatory drugs) — reversibly inhibit the cyclooxygenase pathway, reducing the production of thromboxane and other prostaglandins.